TrialBritish journal of cancer2015

Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.

Alexander Stein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.